GENEDX HOLDINGS CORP (WGS) Stock News
NASDAQ:WGS - Nasdaq - US81663L2007 - Common Stock - Currency: USD
WGS Latest News, Press Relases and Analysis
Wednesday's session: top gainers and losers
Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.
Top stock movements in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Select Medical Lags Q1 Earnings Estimates, Lowers Revenue Outlook
SEM reiterates that earnings for 2025 are likely to be between $1.09 and $1.19 per share.
TDOC Q1 Loss Narrower Than Estimates on Strong Integrated Care Unit
Teladoc Health expects Integrated Care members to be between 101 million and 103 million in 2025.
GeneDx Announces Completion of Fabric Genomics Acquisition
Why Investors Were Avoiding GeneDx Holdings Stock This Week
Why Investors Were Avoiding GeneDx Holdings Stock This Week
The company crushed analyst estimates in its first quarter, but for many investors it didn't crush them enough. Regardless, several analysts cut their price targets just after the earnings release was published. With a nearly 39% stock price decline this week, according to data compiled by S&P Global Market Intelligence, GeneDx Holdings (NASDAQ: WGS) was deep in the doghouse with investors.
GeneDx earnings selloff a buying opportunity, says Craig-Hallum
Craig-Hallum recommends using the post-earnings weakness in shares of GeneDx (WGS) as a buying opportunity. The stock is down over 25% following a “modest” Q1 exome and genome volume miss, which is the company’s first ever sequential decline in volumes, the analyst tells investors in a research note. The firm says management noted Q1 volumes were negatively impacted by significantly worse than expected weather impacts as well as one less day. Encouragingly, GeneDx also saw accelerating volumes i
Hilton price target lowered to $223 from $251 at Truist
Truist lowered the firm’s price target on Hilton (HLT) to $223 from $251 and keeps a Hold rating on the shares after its Q1 results and guidance. The company’s international exposure and new brands help, but the firm has reduced its managed and franchise multiple assumption by 100 bps as Hilton’s C-Corp algorithm looks impaired for now, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> S
Retail Buzz Swirls Around GeneDx As Shares Sink 43% Despite Earnings Beat
GeneDx shares plunged 43% despite strong Q1 results and raised guidance, drawing a surge in retail investor interest. The drop followed the company's first sequential test volume decline, which it linked to weather disruptions.
Why GeneDx Holdings Stock Is Plunging Today
GeneDx beat Wall Street's revenue and adjusted earnings expectations for the first quarter of 2025. Shares of GeneDx Holdings (NASDAQ: WGS) were plunging 42.9% as of 11:21 a.m. ET on Wednesday. GeneDx reported Q1 revenue of $87.1 million, up 42% year over year.
Why GeneDx Holdings Stock Is Plunging Today
Wednesday's session: gap up and gap down stocks
Today's session on Wednesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
IBD 50 Stock GeneDx Hammered Despite Earnings Beat-And-Raise
The company is an expert in using whole genome and exome sequencing to screen for genetic diseases.
Mentions: AAPL
These stocks that are showing activity before the opening bell on Wednesday.
Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
GeneDx Reports First Quarter 2025 Financial Results and Business Highlights
GENEDX HOLDINGS (WGS) Upgraded to Buy: Here's Why
GENEDX HOLDINGS (WGS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GeneDx Holdings Corp. (WGS): Among the Best Multibagger Stocks to Buy According to Billionaires
We recently published a list of 10 Best Multibagger Stocks to Buy According to Billionaires. In this article, we are going to take a look at where GeneDx Holdings Corp. (NASDAQ:WGS) stands against other best multibagger stocks to buy according to billionaires. US Trade tariffs have triggered heightened volatility and amplified the downdraft in the […]
Exploring high growth characteristics of GENEDX HOLDINGS CORP (NASDAQ:WGS).
UA fundamental and technical analysis of (NASDAQ:WGS): nlocking the high Growth Potential of GENEDX HOLDINGS CORP (NASDAQ:WGS).
GeneDx Holdings Corp. (WGS) Rose on Robust Customer Demand
Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. Changing trade, monetary, and fiscal policies increased volatility in US stocks. The emergence of artificial intelligence (AI) models from China added to the uncertainty. Against this backdrop, […]
IBD 50's GeneDx Inks $84 Million AI-Tied Takeover Deal
GeneDx will pay up to $84 million to acquire Fabric Genomics for its AI-powered genomics interpretation platform.
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
